Log in

NASDAQ:FLXN - Flexion Therapeutics Stock Price, Forecast & News

$15.52
-0.80 (-4.90 %)
(As of 02/28/2020 06:00 AM ET)
Today's Range
$15.42
Now: $15.52
$16.41
50-Day Range
$15.52
MA: $17.50
$21.13
52-Week Range
$8.76
Now: $15.52
$22.98
Volume770,986 shs
Average Volume504,743 shs
Market Capitalization$592.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.52 million
Book Value$2.91 per share

Profitability

Net Income$-169,660,000.00
Net Margins-266.51%

Miscellaneous

Employees272
Market Cap$592.40 million
Next Earnings DateN/A
OptionableOptionable

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.


Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) issued its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $0.01. The specialty pharmaceutical company had revenue of $21.79 million for the quarter, compared to analysts' expectations of $18.85 million. Flexion Therapeutics had a negative net margin of 266.51% and a negative return on equity of 271.22%. View Flexion Therapeutics' Earnings History.

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics issued an update on its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $23.7-23.7 million, compared to the consensus revenue estimate of $24.15 million.

What price target have analysts set for FLXN?

9 equities research analysts have issued twelve-month price targets for Flexion Therapeutics' stock. Their forecasts range from $18.00 to $36.00. On average, they expect Flexion Therapeutics' stock price to reach $25.88 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

What is the consensus analysts' recommendation for Flexion Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

Has Flexion Therapeutics been receiving favorable news coverage?

Media stories about FLXN stock have trended positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Flexion Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Flexion Therapeutics.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Cara Therapeutics (CARA), Verastem (VSTM), TherapeuticsMD (TXMD), Gilead Sciences (GILD), AcelRx Pharmaceuticals (ACRX), Omeros (OMER) and Amicus Therapeutics (FOLD).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)
  • Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 58)
  • Scott Young, VP of Corp. Communications & Investor Relations

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (4.36%), Artisan Partners Limited Partnership (2.19%), Gagnon Securities LLC (1.91%), Schroder Investment Management Group (1.60%), Peregrine Capital Management LLC (1.54%) and Geode Capital Management LLC (1.24%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

Which institutional investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Peregrine Capital Management LLC, Campbell Capital Management Inc., UBS Group AG, Gagnon Securities LLC, Bank of America Corp DE, Rafferty Asset Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Flexion Therapeutics.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, State Street Corp, Madison Asset Management LLC, Castleark Management LLC, Cubist Systematic Strategies LLC, EAM Global Investors LLC, EAM Investors LLC and Snow Capital Management LP. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Michael D Clayman and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $15.52.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $592.40 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.View Additional Information About Flexion Therapeutics.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com/.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  520 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  858
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel